In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure $9.3M in funding, announce promising clinical study results, appoint new executives, and much more on the road to LSI USA ‘25 in Dana Point, CA (March 17-21).
Announced the successful completion of enrollment of the Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment (ALL-RISE) randomized controlled trial (RCT). The ALL-RISE Study, spanning 1,924 patients across 59 sites globally, marks a milestone in interventional cardiology by evaluating the clinical and economic impact of the CathWorks FFRangio® System, offering potentially groundbreaking evidence to redefine coronary artery disease care.
Secured $14 Million in Series A-4 funding led by Rapha Capital, with Valitas Venture Capital and eHealth Ventures joining. Over the next year, FIZE Medical plans to expand its platform to include advanced AI-driven patient condition predictions, intra-abdominal pressure measurement, and additional features aimed at enhancing patient care.
Announced that Dr. Gal Noyman-Veksler was named one of The Marker’s “40 Under 40” for 2025, recognizing her exceptional contributions to innovation and leadership. This honor highlights the impact of LionBird’s portfolio companies in advancing global health and technology solutions.
Appointed Prof. Stefan Verlohren as Chairman of its Medical and Scientific Advisory Board. Prof. Verlohren brings extensive expertise in maternal-fetal medicine, reinforcing NeoPredics’ commitment to advancing predictive analytics for neonatal and maternal care.
Closed a $9.3M SAFE funding round led by MTIP, with participation from Techwald Holdings and Elron. The funds will support the company as it prepares for commercialization, regulatory approval, and scaling of its EndoZip endoscopic robotic suturing system.
Announced the results of its clinical study in a peer-reviewed journal, showcasing its noninvasive therapeutic ultrasound technology for peripheral artery disease (PAD) and Chronic Limb Threatening Ischemia (CLTI). This study is the first of the company’s several ongoing clinical research initiatives.
Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.
Schedule an exploratory call
Request InfoMarket Intelligence
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy